NHS England updates CDF List

NHS England has updated the Cancer Drugs Fund List. The latest version (v1.336) was uploaded to the NHS England Website on Friday 6, December 2024.

The following changes have been introduced:

Durvalumab in combination with chemotherapy (DUR3)

For the treatment of neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met

Recommended for routine commissioning, receiving CDF interim funding

Atezolizumab (ATE10)

Atezolizumab monotherapy for adjuvant treatment after complete tumour resection in adult patients with UICC/AJCC 8th edition stage IIB or IIIA or N2 only IIIB non-small cell lung cancer and whose disease is all of the following: has PD-L1 expression on ≥50% of tumour cells, is not EGFR mutant or ALK- positive and has not progressed on recently completed adjuvant platinum-based chemotherapy where the following criteria have been met

Treatment criterion (#5) updated

Nivolumab plus chemotherapy (NIV23)

For the neoadjuvant treatment of adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer and who candidates for potentially curative surgery where the following criteria have been met

Treatment criterion (#4) updated

Pembrolizumab (PEMB30)

Pembrolizumab in combination with chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met

Treatment criterion (#4) updated